P601 Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
Martins, A.(1);Silva, F.(2);Canelas, G.(2);Ribeiro, L.(3);Pinto, S.(3);Sarmento, A.(3);Magro, F.(4);Ferreira de Abreu, C.M.(5)*;
(1)São João Hospital Center- Porto- Portugal Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal Instituto de Inovação e Investigação em Saúde I3S- Portugal d Instituto Nacional de Engenharia Biomédica INEB- Portugal, Infectious Diseases, Porto, Portugal;(2)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(3)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal, Infectious Diseases, Porto, Portugal;(4)Department of Biomedicine- Unit of Pharmacology and Therapeutics- Faculty of Medicine- University of Porto- Porto- Portugal. Department of Gastroenterology- São João Hospital Center- Porto- Portugal. Clinical Pharmacology Unit- São João Hospital Center- Porto- Portugal, Department of Gastroenterology, Porto, Portugal;(5)São João Hospital Center- Porto- Portugal. Department of Medicine- Faculty of Medicine- University of Porto- Porto- Portugal. Instituto de Inovação e Investigação em Saúde I3S- Portugal., Department of Infectious Diseases, Porto, Portugal;
Background
Vaccination is a crucial element in managing patients with IMIDs, however rates of vaccination remains suboptimal. This study assessed the adherence to pneumococcal vaccination.
Methods
A prospective cohort study was conducted between January 2020 and December 2021. Vaccine prescription and adherence were assessed during an Infectious Diseases (ID) consultation. Were considered pneumococcal conjugate (PCV13) and polysaccharide (PPS23) vaccines.
Results
There were 262 patients included (215 with inflammatory bowel disease and 47 with rheumatological diseases), 136 (52%) were male, median age was 41±15 years and 167 (64%) were on immunossuppresive therapy. At baseline, 26 (10%) patients were fully vaccinated against pneumococcal disease and for 236 (90%) vaccination was prescribed as such: PCV13 followed by PPSV23 in 86 (36%) patients, PCV13 in 126 (54%) and PPSV23 in 24 (10%). Adherence to PCV13 occurred in 185 (87%) patients and to PPSV23 in 76 (69%). In patients with both vaccines prescribed (n=86), 57 (66%) had complete adherence and the remaining had at least one of them. In this group (n=86), patients with complete adherence were older than the remaining (45±17 vs. 38±12 years, p=0.03) but no difference was found concerning the baseline disease. After the ID consultation, 175 patients from 236 (74%) became fully vaccinated against pneumococcal disease.
Conclusion
A multidisciplinary approach and adequate local interventions shall be considered to improve vaccine adherence. ID physicians can play a role in the process of increasing vaccine prescription and adherence.